Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer
- 16 July 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (15) , 11045-11062
Abstract
A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring–linkage–B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (11), UT-155 (12), and UT-34 (13). Compound 26f exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, 26f inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.Keywords
Funding Information
- National Cancer Institute (1R01CA229164)
- University of Tennessee Health Science Center
- GTx Incorporated
- Oncternal Therapeutics
This publication has 42 references indexed in Scilit:
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- ARN-509: A Novel Antiandrogen for Prostate Cancer TreatmentCancer Research, 2012
- Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate CancerClinical Cancer Research, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Molecular Mechanisms of Castration-Resistant Prostate Cancer ProgressionFuture Oncology, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling AxisJournal of Clinical Oncology, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 1995
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990